TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27282116
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (2000μg)
Study: 22616628
Drug: GSK679586 (0.005,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK679586 (0.005, 0.05, 0.5, 2.5, 10 mg kg(‐1))
Study: 22616628
Drug: GSK679586 (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK679586 (2.5, 10, 20 mg kg(‐1))
Study: 21818506
Drug: SRD174 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRD174 cream
Study: 6431795
Drug: sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual isosorbide dinitrate (ISDN)
Study: 26799892
Drug: Smartphone-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based intervention program including one Skype session and six weeks of daily directive text messages guiding app use.
Study: 22077909
Drug: Abciximab plus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab plus unfractionated heparin
Study: 18754096
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg every 24 h
Study: 18754096
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg every 12 h (q12h)
Study: 18754096
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 80 mg q12h
Study: 10707752
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose captopril (50 mg b.i.d.)
Study: 10707752
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose captopril (25 mg b.i.d.)
Study: 1357516
Drug: Guaifenesin (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaifenesin (2400 mg daily for 3 weeks)
Study: 3907494
Drug: Oxacillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin plus rifampin (12 g/day, intravenously; rifampin 1,200 mg/day, orally)
Study: 3907494
Drug: Oxacillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin plus placebo (12 g/day, intravenously)
Study: 2439344
Drug: Cisplatin-containing regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin-containing regimen (methotrexate 30 mg/m2, bleomycin 15 mg, hydroxyurea 1000 mg/m2, cisplatin 60 mg/m2)
Study: 2439344
Drug: 3-drug combination
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-drug combination (methotrexate 30 mg/m2, bleomycin 15 mg, hydroxyurea 1000 mg/m2)
Study: 29389467
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of massage and warm-up
Study: 21112549
Drug: Radachlorin® solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radachlorin® solution for intravenous infusions 0.35% 10mL at doses of 0.5‐0.6 and 1.0‐1.2mg/kg
Study: 21112549
Drug: Radachlorin® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radachlorin® gel for topical application 0.1% 25g at a dose of 0.1g/cm(2)
Study: 21112549
Drug: Drug administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administration at a dose of 1.0‐1.2mg/kg and irradiation at 3h with 662±3nm light at a dose of 300J/cm(2) (solution)
Study: 21112549
Drug: 4 PDT
Normalized name: Porfimer sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 PDT sessions at an interval of 1 week with 3h gel exposure, followed by 400J/cm(2) light exposure (gel)
Study: 11003362
Drug: EOS-guided steroid
Normalized name: EO-3021
DrugBank: EO-3021 (DB18358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOS-guided steroid dose adjustment (RG)
Study: 14607663
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg buscopan
Study: 1523144
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg papaverine
Study: 1523144
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.9% NaCl solution
Study: 30666153
Drug: BP-C1 (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP-C1 (0.035 mg/kg bodyweight, daily intramuscular injection for 32 days)
Study: 27634487
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g kg-1)
Study: 24828266
Drug: Minitab sprinkles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minitab sprinkles (40 mg/10 mg)
Study: 18558645
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n=21)
Study: 16858935
Drug: Roselle flower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roselle flower tea (RFT) administered at 4,000 mg in 480 ml of hot distilled water
Study: 11824237
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy (thermal, mechanical, and injection procedures)
Study: 3134556
Drug: Oxamniquine 60
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine 60 mg/kg
Study: 2514474
Drug: Oxamniquine 40
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine 40 mg/kg
Study: 3134556
Drug: Oxamniquine 20
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine 20 mg/kg
Study: 1935730
Drug: Oxamniquine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine (all doses)
Study: 26468074
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 25 μg
Study: 8712444
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 25 mg
Study: 26468074
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine 2 μg/kg
Study: 24529670
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.1 mg/kg/hour)
Study: 21377295
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 μg
Study: 19694865
Drug: Intervention toolkit
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention toolkit including admission form with geriatric cues, facsimile to the primary care provider, interdisciplinary worksheet, pharmacist-physician collaborative medication reconciliation, predischarge planning appointments.
Study: 15254060
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg/d to 1,800 mg/d)
Study: 11229465
Drug: Intraarticular glucocorticoid
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular glucocorticoid treatment (120 mg of methylprednisolone acetate)
Study: 9751468
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg methylprednisolone in mepivacaine 0.25%
Study: 7908257
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg SL 84.0418
Study: 7908257
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg SL 84.0418
Study: 7908257
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SL 84.0418
Study: 3391881
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (EB) 500 mg tid
Study: 3391876
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate (EA) 500 mg tid
Study: 25624132
Drug: 200 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg/d of nasal fluticasone propionate
Study: 23826101
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 and docetaxel 75 mg/m2 (Epi/Doc)
Study: 19433683
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² plus carboplatin AUC = 5 on day 1
Study: 19433683
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² on days 1 and 8 plus carboplatin AUC = 5 on day 1
Study: 16969059
Drug: Primaquine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 30 mg once daily for 7 days (group A, n = 71)
Study: 16969059
Drug: Elubaquine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elubaquine 25 mg once daily for 7 days (group B, n = 70)
Study: 15590356
Drug: Enalaprilat infusion
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalaprilat infusion (0.06 mg/kg/hr) during CPB
Study: 15590356
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dopamine infusion only)
Study: 11704167
Drug: 49-day cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 49-day cycle (42 active pills)
Study: 11704167
Drug: 28-day cycle
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28-day cycle (21 active pills)
Study: 478062
Drug: Sterosan-hydrocortison ointment
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sterosan-hydrocortison ointment
Study: 478062
Drug: Sterosan ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterosan ointment
Study: 478062
Drug: Sterosan cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterosan cream
Study: 478062
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of chlorquinaldol
Study: 25705958
Drug: Propoxyphene/Acetaminophen (PA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene/Acetaminophen (PA)
Study: 22182419
Drug: Behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatments for adolescent marijuana abuse or dependence
Study: 17948223
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by uracil-tegafur 360 mg/m²/day for 16 months
Study: 11867823
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) 250 mg/day
Study: 6222086
Drug: Oral 13-cis-retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 13-cis-retinoic acid at 0.1 mg/kg/day
Study: 6222086
Drug: Oral 13-cis-retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 13-cis-retinoic acid at 0.5 mg/kg/day
Study: 6222086
Drug: Oral 13-cis-retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 13-cis-retinoic acid at 1.0 mg/kg/day
Study: 6222086
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of oral 13-cis-retinoic acid
Study: 6222086
Drug: Clinical response
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical response to treatment
Study: 26914224
Drug: Etomidate 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.15 mg/kg
Study: 26914224
Drug: Etomidate 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.15 mg/kg with hydrocortisone
Study: 22249601
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound with perflutren contrast agent
Study: 15196302
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg intravenous LY293558
Study: 14578014
Drug: Flumazenil (FLU)
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil (FLU) 1 mg twice a day for 8 days
Study: 14578014
Drug: Oxazepam tapering
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam tapering (from 120 mg)
Study: 2499464
Drug: Adenosine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (bolus doses of 5.3 to 15.9 mg)
Study: 2499464
Drug: Theophylline (58.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (58.3 +/- 3.3 mumol l‐1 plasma)
Study: 2499464
Drug: Dipyridamole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (10 mg)
Study: 842760
Drug: Vitamin and
Normalized name: Vitamin and Mineral Supplement
DrugBank: alpha-Tocopherol acetate (DB14003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin and mineral supplement with one‐third of the calories
Study: 30926369
Drug: M1095 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: M1095 (240 mg)
Study: 30926369
Drug: M1095 (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: M1095 (30, 60, 120, or 240 mg)
Study: 27845200
Drug: High-dose KME
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose KME (2g/d)
Study: 27845200
Drug: KME groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: KME groups (low-dose and high-dose)
Study: 26870788
Drug: Linezolid 300
Normalized name: linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 300 mg
Study: 26870788
Drug: Linezolid (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (both doses)
Study: 19262457
Drug: Metilprednisolone (steroids)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metilprednisolone (steroids)
Study: 15272899
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 0.75 mg/kg on alternate days, plus vitamin D 600-1200 units/day and a calcium-enriched diet
Study: 9242341
Drug: Interleukin-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interleukin-1 receptor antagonist (IL-1ra) 100 mg bolus followed by 2 mg/kg per hour intravenously for 72 hours (n = 20)
Study: 8494702
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy including alkylating agents (n = 14)
Study: 15983288
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (0.8 mg/d)
Study: 10372975
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (850 mmol L(‐1))
Study: 10372975
Drug: Time control
Normalized name: BENZOYL PEROXIDE 50 mg in 1 mL TOPICAL LOTION [Nighttime Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time control (no saline infusion)
Study: 4539414
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine (1 dose)
Study: 4539414
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine (2 doses)
Study: 4539414
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine (3 doses)
Study: 4539414
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine (4 doses)
Study: 4539414
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine (1 dose annually for 3 years)
Study: 4539414
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine (2 doses in the first year followed by annual reimmunizations)
Study: 4539414
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine (after 4 doses)
Study: 24377216
Drug: Acupuncture group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture group (shu‐stream point acupuncture combined with fire needle therapy)
Study: 24377216
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (votalin emulgel)
Study: 11738912
Drug: Ciprofloxacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (2 oral 500 mg doses at 12-hour intervals)
Study: 11738912
Drug: Levofloxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (single oral 500 mg dose)
Study: 11738912
Drug: Moxifloxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (single oral 400 mg dose)
Study: 8996152
Drug: Mitomycin as
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin as an adjunct to radiation therapy
Study: 8214177
Drug: Social support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support group therapy (8 sessions)
Study: 3677279
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (0.4 ml.kg‐1)
Study: 28947724
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rivaroxaban
Study: 27716128
Drug: Tailored Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored Treatment (TT)
Study: 27716128
Drug: Non-Tailored Treatment
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Tailored Treatment (NTT)
Study: 24534128
Drug: Eptifibatide plus
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide plus rt-PA (0.6 mg/kg rt-PA, 135 mcg/kg bolus, 0.75 mcg/kg/min two-hour infusion)
Study: 24534128
Drug: rt-PA alone
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA alone (0.9 mg/kg)
Study: 20613484
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (5, 10, 15, 20, 30, or 40 mg)
Study: 20613484
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine (7, 15, 20, 30, 45, or 60 mg)
Study: 18756037
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (154 mmol/L intravenous infusion, bolus of 3 ml.kg(‐1).h(‐1) for 1 h before contrast, followed by infusion of 1 ml.kg(‐1).h(‐1) for 6 h during and after the procedure)
Study: 18756037
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (154 mmol/L intravenous infusion, bolus of 3 ml.kg(‐1).h(‐1) for 1 h before contrast, followed by infusion of 1 ml.kg(‐1).h(‐1) for 6 h during and after the procedure)
Study: 16738029
Drug: High ranking
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ranking competitors (e.g., #2 vs. #3)
Study: 16738029
Drug: Low ranking
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low ranking competitors (e.g., #202 vs. #203)
Study: 16738029
Drug: Proximity to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximity to meaningful standards (e.g., bottom of a ranking scale or qualitative threshold)
Study: 11731729
Drug: labetalol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol 0.2 mg/kg
Study: 11731729
Drug: urapidil 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil 25 mg
Study: 7864425
Drug: no drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: no drug
Study: 2956872
Drug: Enoximone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (150 mg, 3 times daily)
Study: 2956872
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg, 3 times daily)
Study: 2956872
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional therapy with diuretics)
Study: 20149361
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist ganirelix
Study: 31790144
Drug: Ketoconazole (steroidogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (steroidogenic inhibitor)
Study: 31790144
Drug: High-dose ganirelix
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ganirelix and repeated LH infusions
Study: 19057210
Drug: PDE-5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE-5 inhibitors (sildenafil, vardenafil, tadalafil)
Study: 9663723
Drug: OCT (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCT (omeprazole 20 mg q.d.s. + clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.)
Study: 9663723
Drug: CT (clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.)
Study: 9663723
Drug: OC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC (omeprazole 20 mg o.d. + clarithromycin 250 mg b.d.)
Study: 9663723
Drug: C (clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (clarithromycin 250 mg b.d.)
Study: 9663723
Drug: OCT (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCT (in patients with pre-treatment metronidazole resistance)
Study: 9663723
Drug: CT (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (in patients with pre-treatment metronidazole resistance)
Study: 9663723
Drug: C (post-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (post-treatment resistance to clarithromycin)
Study: 9663723
Drug: OC (post-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC (post-treatment resistance to clarithromycin)
Study: 9663723
Drug: CT (post-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (post-treatment resistance to both antibiotics)
Study: 9663723
Drug: OCT (post-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCT (post-treatment resistance to both antibiotics)